Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years

被引:7
|
作者
Ye, Yanna [1 ,2 ]
Li, Zhiqiang [1 ]
Kang, Shan [3 ]
Zhan, Xuemei [4 ]
Zhang, Yi [5 ]
Xu, Yan [6 ]
Li, Weili [2 ]
Lang, Jinghe [2 ,7 ]
Liu, Ping [2 ]
Chen, Chunlin [1 ,2 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, 1838 Guangzhou Ave, Guangzhou 510515, Peoples R China
[2] Dongguan Polytech, Fac Hlth, Dept Midwifery, Dongguan, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Gynecol, Shijiazhuang, Peoples R China
[4] SEN Univ, Affiliated Jiangmen Hosp SUN YAT, Dept Obstet & Gynecol, Jiangmen, Peoples R China
[5] China Med Univ, Dept Gynecol, Hosp 1, Shenyang, Peoples R China
[6] Pan Yu Cent Hosp, Dept Obstet & Gynecol, Guangzhou, Peoples R China
[7] Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
cervical cancer; disease-free survival; intermediate-risk pathological factor; oncological outcome; overall survival; postoperative adjuvant therapy; RADICAL HYSTERECTOMY; PELVIC IRRADIATION; RADIATION-THERAPY; RANDOMIZED-TRIAL; CARCINOMA; CHEMOTHERAPY; IB; RADIOTHERAPY; CISPLATIN; METASTASIS;
D O I
10.1111/jog.15632
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare survival outcomes of different postoperative adjuvant therapies (PATs) for early-stage cervical cancer (ECC) patients with one intermediate-risk pathological factor (IPF).Methods: A total of 2889 patients with stage IA1 to IIA2 cervical cancer were included in this study. Three PAT groups were identified, namely a no adjuvant therapy (NAT) group (n = 773), an adjuvant radiotherapy/chemoradiotherapy (ART) group (n = 1648) and an adjuvant chemotherapy (ACT) group (n = 468). Kaplan-Meier analysis and COX regression analysis were used to compare the overall survival (OS) and disease-free survival (DFS) among the three groups, before and after propensity score matching (PSM).Results: The recurrence and mortality rate rates in the NAT, ART and ACT groups were 9.2%, 8.6%, and 7.9%, respectively (p = 0.737). Kaplan-Meier analysis demonstrated no significant differences in the NAT, ART, and ACT groups in 5-year OS rates (92.8% vs. 93.6% vs. 94.7%, p = 0.594) and DFS rates (88.7% vs. 89.6% vs. 90.5%, p = 0.772). Post-hoc tests yielded similar results, with no differences in 5-year OS and DFS (NAT vs. ART, before and after matching, p > 0.05); (NAT vs. ACT, before and after matching, p > 0.05); and (ACT vs. ART, before and after matching, p > 0.05).Conclusion: Postoperative adjuvant radiotherapy, chemoradiotherapy, and chemotherapy are not associated with survival outcomes of ECC patients with one IPF. Considering the side effects and impact on patients' quality of life, the PATs should be carefully considered.
引用
下载
收藏
页码:1579 / 1591
页数:13
相关论文
共 50 条
  • [21] MRI radiomics nomogram integrating postoperative adjuvant treatments in recurrence risk prediction for patients with early-stage cervical cancer
    Ai, Yao
    Zhu, Xiaoyang
    Zhang, Yu
    Li, Wenlong
    Li, Heng
    Zhao, Zeshuo
    Zhang, Jicheng
    Ning, Boda
    Li, Chenyu
    Zheng, Qiao
    Zhang, Ji
    Jin, Juebin
    Li, Yiran
    Xie, Congying
    Jin, Xiance
    RADIOTHERAPY AND ONCOLOGY, 2024, 197
  • [22] The effect of adjuvant radiotherapy on oncological outcomes in patients with early-stage cervical carcinoma with only intermediate-risk factors: a propensity score matching analysis
    Turkmen, Osman
    Kilic, Fatih
    Tokalioglu, Abdurrahman Alp
    Cakir, Caner
    Yuksel, Dilek
    Kilic, Cigdem
    Boran, Nurettin
    Comert, Gunsu Kimyon
    Turan, Taner
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 42 (07) : 3204 - 3211
  • [23] Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer
    Jin, Meng
    Hou, Xiaorong
    Sun, Xiansun
    Zhang, Yuelun
    Hu, Ke
    Zhang, Fuquan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (08) : 1264 - 1270
  • [24] Survival outcomes of low-risk and intermediate-risk stage IB1 cervical cancer patients
    Vanichtantikul, Asama
    Tantbirojn, Patou
    Manchana, Tarinee
    ASIAN BIOMEDICINE, 2019, 13 (01) : 27 - 32
  • [25] Adjuvant pelvic radiation versus observation in intermediate-risk early-stage cervical cancer patients following primary radical surgery: a propensity score-adjusted analysis
    Tuscharoenporn, Thunwipa
    Muangmool, Tanarat
    Charoenkwan, Kittipat
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (04)
  • [26] Can Chemotherapy Boost the Survival Benefit of Adjuvant Radiation Therapy in Early-Stage Cervical Cancer With Intermediate Risk Factors: A Population-Based Study
    Mahmoud, O. M. E. E.
    Gabel, M.
    Gibbon, D.
    Leiser, A.
    Isani, S.
    Cracchiolo, B.
    Khan, A. J.
    Elshaikh, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E287 - E287
  • [27] Adenocarcinoma in situ or early-stage cervical cancer is a risk factor for preterm delivery after cervical conization: a multicenter observational study
    Kasuga, Yoshifumi
    Ikenoue, Satoru
    Nishio, Hiroshi
    Yamagami, Wataru
    Ochiai, Daigo
    Tanabe, Kiyoo
    Tashima, Yasuhiro
    Hirao, Nobumaru
    Miyakoshi, Kei
    Kasai, Kenji
    Suda, Yoshio
    Nemoto, Taiko
    Shiraishi, Satoru
    Yoshida, Hiroyuki
    Kurahashi, Takashi
    Takamatsu, Kiyoshi
    Iwasaki, Shinya
    Yamashita, Hiroshi
    Akiba, Yasuo
    Arase, Toru
    Hara, Sumiko
    Nakada, Sakura
    Tanaka, Mamoru
    Aoki, Daisuke
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2022, 35 (25): : 9837 - 9842
  • [28] Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients
    Ryu, HS
    Chun, M
    Chang, KH
    Chang, HJ
    Lee, JP
    GYNECOLOGIC ONCOLOGY, 2005, 96 (02) : 490 - 495
  • [29] Risk Stratification of Early-Stage Cervical Cancer with Intermediate-Risk Factors: Model Development and Validation Based on Machine Learning Algorithm
    Chu, Ran
    Zhang, Yue
    Qiao, Xu
    Xie, Lin
    Chen, Wei
    Zhao, Ying
    Xu, Yintao
    Yuan, Zeng
    Liu, Xiaolin
    Yin, Aijun
    Wang, Zhiwen
    Zhang, Qing
    Yang, Xingsheng
    Su, Xuantao
    Kong, Beihua
    Song, Kun
    ONCOLOGIST, 2021, 26 (12): : E2217 - E2226
  • [30] Disease-free survival (A) and overall survival (B) of intermediate-risk cervical cancer patients divided by administration of adjuvant treatment
    Alonso-Espias, Maria
    Hernandez, Alicia
    Alonso-Garcia, Marcos
    Gracia, Myriam
    Garcia-Pineda, Virginia
    Siegrist, Jaime
    Dolores Diestro, Maria
    Arnedo, Rocio
    Zapardiel, Ignacio
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A44 - A45